ARCHIVES

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 8 | August 26, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

Toxicity Of Salts Regimen Should Remain A Concern.

January 4, 2002

NIH Forming Special Emphasis Panel To Review Clinical Oncology Grants

September 18, 1998

NCI-Approved Clinical Trials

March 31, 2006

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

April 10, 1981

Fruit, Candy Flavored Cigarettes Banned In U.S.; FDA To Examine Menthol Flavored Tobacco

September 25, 2009